Compounds > fluorodopa f 18
Page last updated: 2024-08-24

fluorodopa f 18 and Malignant Carcinoid Syndrome

fluorodopa f 18 has been researched along with Malignant Carcinoid Syndrome in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brouwers, AH; De Hooge, MN; De Vries, EG; Jager, PL; Kema, IP; Koopmans, KP; Van der Horst-Schrivers, AN; Wolffenbuttel, BH1
Balard, M; de Beco, V; Grahek, D; Gutman, F; Kerrou, K; Montravers, F; Nataf, V; Talbot, JN1

Other Studies

2 other study(ies) available for fluorodopa f 18 and Malignant Carcinoid Syndrome

ArticleYear
Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:7

    Topics: Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Liver Neoplasms; Malignant Carcinoid Syndrome; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals

2005
Safety of 18F-DOPA injection for PET of carcinoid tumor.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:10

    Topics: Carcinoid Tumor; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Injections, Intravenous; Malignant Carcinoid Syndrome; Positron-Emission Tomography; Radiopharmaceuticals

2006